The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
Researchers saw frequent somatic mutations in esophageal tissue from nine individuals, including mutations under positive selection in 14 oncogenes.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Exome sequences from thousands of Chinese individuals with or without esophageal squamous cell carcinoma led to six new germline risk variants.
In an initial project, the research team is sequencing esophageal tumor genomes of patients in Tanzania, where it is one of the most common cancers.
Higher levels of oral bacteria like Tannerella forsythia and Porphyromonas gingivalis increased the risk of esophageal cancer, though other bacteria had protective effects.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.